"A Phase I/IIA Dose-Escalating Trial of bcl-2 Antisense (G3139) Treatment by 14-Day Continuous Intravenous Infusion (CI) for Patients with Androgen-Indep

According to an abstract submitted by the authors to the 35th Annual Meeting of the American Society of Clinical Oncology, held May 15-18, 1999, in Atlanta, Georgia, "The bcl-2 proto-oncogene encodes an inner mitochondrial protein that inhibits apoptosis. Bcl-2 overexpression has been implicated in the growth and chemoresistance of a variety of solid tumors including breast, lung, kidney, and androgen-independent prostate cancers. G3139 (Genta Incorporated) is an 18-base bcl-2 antisense oligonucleotide shown to induce regression of relapsed lymphomas when given as a 14-day subcutaneous infusion. Preclinical data indicate that therapeutic effects are seen when plasma concentrations are...

Want to see the full article?

• Purchase this article for only $3.00